Overview

Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid

Status:
Withdrawn

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

This randomized clinical trial studies genetics in predicting risk of bisphosphonate-related osteonecrosis of the jaw in patients with cancer receiving zoledronic acid. Zoledronic acid is an anti-resorptive drug used as part of cancer treatment. A serious side effect of these drugs is death of the jawbone, commonly called bisphosphonate-related osteonecrosis of the jaw (BRONJ). Genetic research may help doctors understand risk factors for BRONJ or who is more likely to get BRONJ and why.

Phase:

N/A

Details

Lead Sponsor:

University of Southern California

Collaborator:

National Cancer Institute (NCI)

Treatments:

Diphosphonates
Zoledronic Acid